Discussion
Our results confirm other reports of the clinical effectiveness of this therapy (Anderson and Arner, 1972; Edwards et al., 1973) and so justify the plan to synthesize this analogue of vasopressin (Zoral and Storm, 1966) . Twice-daily intranasal DDAVP completely controlled the diabetes insipidus in all our patients. Included were patients whose severe diabetes insipidus could not be controlled by chlorpropamide even when supplemented with LVP nasal spray and so had been managed with intramuscular vasopressin tannate in oil. The intranasal DDAVP method of treatment was preferred by all the patients and also achieved better control of their diabetes insipidus without any side effects.
There is no doubt that there was a need for this improvement in the replacement therapy of vasopressinsensitive diabetes insipidus. Unfortunately nephrogenic diabetes insipidus can still only be poorly controlled by the use of thiazides and restricting salt intake (Schotland et al., 1963) . For mild cases of vasopressin-sensitive diabetes insipidus oral chlorpropamide (Wales and Fraser, 1971) , clofibrate (De Gares et al., 1970) , or carbamezipine (Braunhofer and Zicha, 1966) has been proved fully adequate. Slightly more severe cases may be fully controlled if one of these drugs is supplemented by intranasal LVP (Wales and Fraser, 1971) . But hitherto for severe vasopressin-sensitive diabetes insipidus adequate control has been possible only with intramuscular vasopressin tannate in oil, whose duration of action often varies from inadequate shaking and warming of the phial before injection.
DDAVP is an improvement in several ways. The pure synthetic compound can be given intranasally without causing rhinitis or even the severe pulmonary reactions produced at times by vasopressin snuff (Pepys et al., 1965; Mahon et al., 1967) and years of rhinitis from this snuff may subside when the patient changes from the snuff to intranasal DDAVP, as our case 2 showed. Administration of accurately measured dosage can be achieved with the nasal catheter method of administration (Rhinyl, Ferring A.B.) . As hoped by the synthesists (Zoral and Storm, 1966 ) the amino-acid substitutions involved have eliminated the pressor effects from the doses needed for replacement therapy and produced resistance to degradation so that it persists longer at the site of action (Vara et al., 1968; Edwards et al., 1973) (Odell et al., 1967; Hall, 1972) (Hedley et al., 1971) . Similar observations have been made in patients treated with radioactive iodine (Slingerland et al., 1972; Toft et al., 1973) . The term subclinical hypothyroidism has been used to describe patients who fall into this category (Hall, 1972 mal range of serum TSH was < 1-0-4-5 ,tU/ml; within assay variation was 2-5% and between assay variation was 15%. Thyrotrophin-releasing hormone (TRH) tests were carried out as described by Tunbridge et al. (1973) . Serum cholesterol was determined using Technicon method N24a (normal range 140-260 mg/100 ml). Free T.B.G. capacity was measured using a Sephadex column (Gimlette, 1967 Group 5.-Four patients were asymptomatic and clinically euthyroid, but the results of the tests were on balance indicative of hypothyroidism. Serum cholesterol was raised in all four patients (range 330-370 mg/ 100 ml). Values for at least two of the other three routine thyroid function tests (PBI, serum T-4, free T.B.G. capacity) were below the lower limit of the normal range. TSH levels were raised (see fig.) , but in two of the three patients for whom results were available serum T-3 values were normal (850 and 920 pg/ml). A third patient had a serum T-3 of 600 pg/ml. All four patients were given a therapeutic trial of thyroxine. Two felt no better and showed no changes clinically, but their serum cholesterol fell significantly after a month on 0-1 mg of thyroxine and became normal after the dose was increased to 0-2 mg. For this reason treatment was continued. The third patient did not feel well on thyroxine and there was no significant fall in serum cholesterol. Treatment was therefore discontinued. The remaining patient, a woman aged 77, had both low serum T-4 and low serum T-3 levels. She tolerated treatment with thyroxine, which was gradually increased to 0-15 mg daily and her serum cholesterol fell significantly. Two weeks after she had been discharged from hospital she had a myocardial infarct, and treatment with thyroxine was accordingly discontinued. She subsequently developed overt symptoms and signs of hypothyroidism.
Group 6.-Nine patients were hypothyroid by all criteria including raised TSH levels. (See fig.) They all responded to treatment with thyroxine.
COMPARISON OF GROUPS 3 AND 4
Mean values of P.B.I. serum T-4, serum T-3, free T.B.G. 91 capacity, and serum cholesterol for the patients in groups 3 and 4 are compared in table II. The patients in group 3 had a significantly higher P.B.I. (P < *001) and serum T4 (P < 01) than those in group 4 though for both groups all values were within the normal range. Serum cholesterol, on the other hand, was significantly higher for the patients in group 4 than for those in group 3 (P < -001 Recurrent hyperthyroidism is rarely seen after "II therapy. In thlis series there were two patients who were unquestionably hyperthyroid and five others (group 2) who though clinically euthyroid must be considered hyperthyroid on the basis of their tests. The two patients who were recognized as being thyrotoxic had both been treated with an anti-thyroid drug after their treatment with "'lI and it is likely that they relapsed after having had temporary drug-induced remissions.
The patients in group 2 presented considerable problems from both the diagnostic and therapeutic viewpoint. Most of them had been attending the clinic for several years. There was nothing in their records to suggest that they might have residual hyperthyroidism. They were asymptomatic and on clinical examination euthyroid. Routine thyroid function tests showed raised levels of circulating thyroxine which could not be attributed to any abnormality in the thyroid hormone binding proteins, and the TRH test result was consistent with hyperthyroidism. Though treatment with carbimazole for a month induced a significant fall in the P.B.I. none of the patients seemed to derive any clinical benefit from this pro-I I cedure. It is difficul-t to offer any explanation for the lack of correlation between clinical state and test results in these patients who could be regarded as having subclinical hyperthyroidism (Hall et al., 1973) .
The four patients in group 5 presented a similar sor,t of problem to those in group 2 though in this case the question was whether or not they were hypothyroid. Clinically they seemed to be euthyroid but they had low serum T-4 levels. Serum T-3 levels in two of these patients on the other hand were within the normal range. Some patients who have been treated with 13II have been found to have low serum T4 levels in association with raised or normal serum T-3 levels (Sterling et al., 1969 , Bellabarba et al., 1972 , and it has been suggested that normal thyroid status is achieved in this situation by an alteration in the serum T3 T4 ratio. It was to be expected that among the patients we surveyed there would be some who showed this phenomenon. I,t seems that at least two of the patients in this group were euthyroid, perhaps because they were preferentially producing T-3. We conclude that the 77-year-old woman who did have a low serum T-3 level and the highest TSH value recorded in the series (see fig.) was in fact hypothyroid despite the absence of a therapeutic response to thyroxine. It is generally agreed that the secretion of thyroid hormone is regulated by means of a feedback mechanism. According to this concept TSH levels can be expected to increase when blood concentrations of T-3 or TA or both are suboptimal. It would seem that the feedback mechanism is essentially normal in patients with thyrotoxicosis whether the condition is active or in remission after treatment. (Adams and Kennedy, 1965; Pinchera et al., 1965) . Eighty five (81 %) of the patients we investigated were assessed as being euthyroid on the basis of clinical examination and thyroid function tests, but 39 (46%) of these patients had raised TSH levels. The implication is that nearly half the patients who seemed to be euthyroid were suffering from thyroid hormone insufficiency.
It could be argued that the T-4 levels in the euthyroid patients with raised serum TSH levels though falling within our observed normal range were nevertheless below the optimum levels for this particular group of individuals. In support of this argument is the fact that these patients had lower levels of T-4 than the group 3 patients. If group 3 were indeed euthyroid then the raised serum TSH levels in the group 4 patients could be attributed to suboptimal levels of T4, an explanation which is consistent with conventional views about the feedback mechanism. The mean serum cholesterol level was higher in group 4 patients than in group 3 patients and this might also be interpreted as evidence of thyroid hormone insufficiency. There was, however, no decrease in the serum cholesterol levels when the patients were given thyroxine though serum TSH levels did fall to within the specified normal range.
The mean value for serum T-4 in the group 4 patients was 8-3 ,ug/100 ml, which is very close to our mean value for normal subjects (86 ug/I100 ml). It seems unlikely t-herefore that they had inadequate levels of T-4 unless before the onset of thyrotoxicosis they constituted a group having a mean T-4 level higher than that of nonnal people. There was no difference in serum T-3 levels between groups 3 and 4, and furthermore, all serum T-3 values for both groups fell within the normal range. It was impossible to measure serum T-3 in all the euthyroid patients, but there are probably enough values to be representative of each group as a whole. Since both serum T-4 and serum T-3 levels were within normal limits it is difficult to concede that the patients in group 4 were suffering from thyroid hormone insufficiency. In reaching this conclusion we 
